Provention Bio, Inc., a clinical-stage biopharma company developing therapeutics for immune-mediated diseases, has entered into agreements with MacroGenics, Inc. to acquire all rights to teplizumab (to be further developed as PRV-031) and licensing rights to MGD010 for development as PRV-3279.   MacroGenics will receive a warrant to purchase a minority equity interest in Provention and will be eligible to receive future milestone payments and royalties on future net sales.   PRV-031, a human...